Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS
Authors' conclusion
In patients with T2D, higher NT-proBNP level, TnT level and BMI are independent and externally validated predictors of new-onset HF, including patients using an SGLT2 inhibitor. This newly developed model may identify patients at high risk of new-onset HF, contributing to early recognition and possibly prevention.
Study context
- Population
- Patients with T2D with albuminuria or CVD (ALTITUDE) and no history of heart failure (HF); validated in CANVAS
- Outcome
- New-onset HF (prediction model performance, C-statistic)
Methodological detailsCox regression
- Cox regression
Performance
As reported in the abstract
C-statistic of the prediction model for new-onset HF
ALTITUDE
0.828
C-statistic · 95% CI 0.801–0.855
CANVAS placebo
0.800
C-statistic · 95% CI 0.720–0.880
Further findings
| Outcome | Values |
|---|---|
| C-statistic after 1 year of canagliflozin treatment | Canagliflozin C-statistic 0.847 (95% CI 0.792–0.902) |
| Baseline characteristics, ALTITUDESerum NT-proBNP | ALTITUDE median 157 (IQR 70–359) pg/mL · mean age 64 ± 9.8 years |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS. Diabetes Obes Metab. Published 8 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →